Comparative Pharmacology
Head-to-head clinical analysis: CROMOPTIC versus INTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOPTIC versus INTAL.
CROMOPTIC vs INTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
None Documented
None Documented
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer